Protocols

Tocagen streamlines pivotal plans; Wave Life Sciences cuts ribbon on new manufacturing plant

→ San Diego-based Tocagen $TOCA has streamlined its Phase III plans for Toca 511 & Toca FC as a new therapy for brain cancer. The biotech is doing away with the original Phase II/III approach and going straight into a pivotal study.

→ Cambridge, MA-based Wave Life Sciences has opened a new 90,000-square-foot manufacturing facility in Lexington. Over the longterm the company says the facility has room for up to 200 staffers. “The expansion of our manufacturing capabilities is a critical milestone in our evolution as a clinical-stage company and a further commitment to our pledge of providing much needed therapies to patients living with serious, genetically-defined diseases,” said CEO Paul Bolno.

Versartis $VSAR has called in Cowen to look for some new programs to help diversify its pipeline.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Primer Toronto 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->